AlphAIAlphAI — Financial news for AI agents
leaderpost.comSEP 11 min read$VIVS

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

VivoSim Labs (Nasdaq: VIVS) plans to develop a rat liver model to complement its human liver platform, aiming to help pharma companies distinguish rat-specific toxicity from human risks. The model is designed to validate compounds with known toxicity differences between rats and humans, potentially broadening the utility of its NAMkind™ platform. The company believes this addition could strengthen its position in liver toxicology and accelerate commercial growth.

Original reporting
leaderpost.com
Published Sep 1, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 1:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$VIVS
Neutral
medium confidence
Mentioned
$VIVS
Relevance
5/10
AlphAI data visualization · based on leaderpost.com
Decision brief

The 30-second read

$VIVSNeutralLow
01

Why it matters

The announcement signals strategic growth but lacks immediate financial impact.

02

Market read

Introduces a new preclinical tool that could attract pharma contracts, modestly influencing VivoSim's valuation.

03

What to watch

Regulatory acceptance timeline and competitive landscape for animal alternative models.

Relevance 5/10Novelty 6/10Timing: Sept. 1, 2026 (today)

Background

VivoSim Labs provides 3D human tissue models for drug safety testing and is expanding its portfolio.

Company-level read

Ticker impact

$VIVSNeutralMedium confidence
Context

VivoSim Labs announced plans to develop a rat liver model to complement its human liver platform, a first-time product expansion.

Expected impact

Modest upside if investors view the expansion as revenue growth catalyst.

Evidence & confidence

New capability may attract additional pharma contracts, but no financial metrics disclosed.

Market effects

Sector

Enhances the preclinical toxicology sector's shift toward NAM approaches.

Regional

May benefit US biotech service providers.

Global

Supports global pharma R&D trends favoring human-relevant models.

Counterpoint

What could challenge this read

The rat model may dilute focus on the core human platform and strain resources.

Key entities

  • Company
    VivoSim Labs, Inc.

    Provider of NAM 3D human cellular models.

  • Executive
    Keith Murphy

    Executive Chairman of VivoSim Labs.

Read at source← All news

Related articles

OCT 7
$VIVSMed

FDA updates regulations to allow non-animal drug safety testing

The FDA updated regulations to allow non-animal methods for drug safety testing, replacing 'animal tests' with 'nonclinical tests'. VivoSim Labs (VIVS) offers 3D human cellular models for preclinical testing, aiming to reduce drug development costs by identifying toxic molecules early. The company's models use primary human cells and could help avoid costly failures in clinical trials.

investing.com2 min
OCT 7
$VIVSMed

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

VivoSim Labs (VIVS) welcomes FDA's updated regulations allowing greater use of non-animal testing methods. The rule replaces 'animal tests' with 'nonclinical tests,' benefiting VivoSim's 3D human cellular models. VivoSim's models can identify drug safety risks earlier, reducing development costs. The company expects accelerated adoption of its NAM models following the FDA's roadmap.

globenewswire.com2 min
AUG 6
$VIVSMedAI 8/10

VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 – Minichart

VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.

minichart.com.sg5 min
AUG 6
$VIVSMed

VivoSim Provides Financial and Listing Compliance Update

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VivoSim Provides Financial and Listing Compliance Update San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, t

SEC EDGAR 8-K2 min
AUG 6
$VIVSMed

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.

stocktitan.net4 min